KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medpace Holdings (MEDP) EBIT (2016 - 2026)

Medpace Holdings filings provide 12 years of EBIT readings, the most recent being $141.5 million for Q1 2026.

  • On a quarterly basis, EBIT rose 24.65% to $141.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $562.9 million, a 23.36% increase, with the full-year FY2025 number at $534.9 million, up 19.71% from a year prior.
  • EBIT hit $141.5 million in Q1 2026 for Medpace Holdings, down from $153.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $153.3 million in Q4 2025 to a low of $60.2 million in Q2 2022.
  • Median EBIT over the past 5 years was $104.1 million (2024), compared with a mean of $102.3 million.
  • Biggest five-year swings in EBIT: soared 44.89% in 2022 and later grew 9.08% in 2025.
  • Medpace Holdings' EBIT stood at $76.4 million in 2022, then rose by 14.25% to $87.3 million in 2023, then soared by 43.58% to $125.4 million in 2024, then grew by 22.25% to $153.3 million in 2025, then decreased by 7.68% to $141.5 million in 2026.
  • The last three reported values for EBIT were $141.5 million (Q1 2026), $153.3 million (Q4 2025), and $141.8 million (Q3 2025) per Business Quant data.